关于实际控制人收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）接到实际控制人陆克平先 生通知，陆克平先生于 2023 年 12 月 23 日收到中国证券监督管理委员会下发的 《立案告知书》（编号：证监立案字 0062023039 号），因涉嫌信息披露违法违 规，根据《中华人民共和国证券法》、《中华人民共和国行政处罚法》等法律法 规，中国证券监督管理委员会决定对其立案。 经公司自查，陆克平先生被立案调查的事项与本公司无关。在立案调查期间， 陆克平先生将积极配合中国证券监督管理委员会的相关工作。公司将持续关注上 述事宜相关进度，并按照有关法律法规等的规定和要求，及时做好信息披露工作。 目前，公司日常经营管理和业务状况正常。 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公 告 编 号 ： 临 - 2 0 2 3 - 4 8 号 江苏四环生物股份有限公司 公司将密切关注后续进展，并按照相关规定履行信息披露义务，敬请投资者 注意投资风险。 2023 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公 告 编 号 ： 临 - 2023 - 4 7 号 江苏四环生物股份有限公司 关于变更签字注册会计师的公告 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公 告不存在虚假记载、误导性陈述或者重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日召开 了第九届董事会第十八次会议，审议通过了《关于续聘公司 2023 年度审计机构 的议案》，公司续聘中审亚太会计师事务所（特殊普通合伙）（以下简称"中审 亚太"）为公司 2023 年度审计机构，本议案已经 2023 年 5 月 17 日召开的 2022 年年度股东大会审议通过。公司于近日收到中审亚太出具的《关于变更签字注册 会计师的函》，具体情况如下： 签字注册会计师王晓林女士，2017 年成为中国注册会计师，为多家公司提 供过新三板年报审计和上市公司年报审计等证券服务，具备专业胜任能力。 王晓林女士不存在违反《中国注册会计师职业道德守则》有关独立性要求的 情形，最近三年未曾因执业情况受到过刑事处罚、行政处罚、行政监管措施和自 律处分 ...

公司于今日收到实际控制人陆克平先生部分股份的解除质押登记通知及质 押登记通知，具体情况如下： 江苏四环生物股份有限公司 关于实际控制人部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 实际控制人陆克平先生持有公司股份 317,664,846 股，截止公告日，累计质 押股份数量 285,990,000 股，占其所持公司股份数量的 90.03%；累计被司法冻 结股份数量 18,725,100 股，占其所持公司股份数量的 5.89%，请投资者注意相 关风险。 根据中国证监会向江苏四环生物股份有限公司（以下简称"公司"）送达的 《行政处罚决定书》（【2020】17 号）所述，陆克平拥有陆宇、郁琴芬、孙现、 郁叙法、周军、张惠丰、徐瑞康、赵龙、许稚、陈建国、王洪明、孙一帆、江苏 德源纺织服饰有限公司等账户的控制权，且其与赵红、华樱、倪利锋、何斌存在 一致行动关系，构成一致行动人，不晚于 2014 年 5 月 23 日成为公司的实际控制 人（具体内容详见公司临 2020-22 号公告）。 股 票 代 码 ： 0 0 0 5 1 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公 告 编 号 ： 临 - 2023 - 4 5 号 江苏四环生物股份有限公司 二、公司关注并核实的相关情况 经与公司第一大股东、实际控制人、公司董事会及管理层进行核实，就有关 情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、近期公共传媒未报道可能或已经对本公司股票交易价格产生较大影响的 未公开重大信息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、公司、公司第一大股东、实际控制人不存在关于本公司的应披露而未披 露的重大事项。 关于股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 江苏四环生物股份有限公司（以下简称"公司"）股票(证券简称：四环生 物，证券代码：000518)连续两个交易日（2023 年 11 月 24 日、2023 年 11 月 27 日）收盘价涨幅偏离值累计超过 20%，根据深圳证券交易所的有关规定，属于股 票交易异常波动的情况。 5、公司第一大股东、实际控制人在公司股票交易异常 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公 告 编 号 ： 临 - 2 0 2 3 - 4 4 号 江苏四环生物股份有限公司 关于股票交易异常波动公告 4、公司、公司第一大股东、实际控制人不存在关于本公司的应披露而未披 露的重大事项。 5、公司第一大股东、实际控制人在公司股票交易异常波动期间未买卖公司 股票。 三、是否存在应披露而未披露信息的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 江苏四环生物股份有限公司（以下简称"公司"）股票(证券简称：四环生 物，证券代码：000518)连续两个交易日（2023 年 11 月 22 日、2023 年 11 月 23 日）收盘价涨幅偏离值累计超过 20%，根据深圳证券交易所的有关规定，属于股 票交易异常波动的情况。 二、公司关注并核实的相关情况 经与公司第一大股东、实际控制人、公司董事会及管理层进行核实，就有关 情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、近期公共传媒未报道可能或已经对本公司股票交易价格产生较大影响的 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2023 - 4 3 号 江苏四环生物股份有限公司 关于实际控制人部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 实际控制人陆克平先生持有公司股份 317,616,846 股，截止公告日，累计质 押股份数量 285,990,000 股，占其所持公司股份数量的 90.04%；累计被司法冻 结股份数量 18,725,100 股，占其所持公司股份数量的 5.90%，请投资者注意相 关风险。 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2023 - 4 3 号 | 称 | 股股东或 | 押股数 | 持 | 股 | 司总 | 为限 | 为补 | | 日 | | 日 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

Financial Performance - The company's revenue for Q3 2023 was ¥58,524,256.85, a decrease of 25.19% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥5,542,080.66, representing a decline of 128.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥5,553,105.45, down 121.53% from the previous year[5]. - Total operating revenue for Q3 2023 was CNY 179,935,611.58, a decrease of 8.4% compared to CNY 196,626,339.15 in the same period last year[17]. - Net loss for Q3 2023 was CNY 46,056,930.81, compared to a net loss of CNY 38,626,058.29 in Q3 2022, representing an increase in loss of 19.0%[18]. - Basic and diluted earnings per share were both CNY -0.0421, compared to CNY -0.0343 in the same quarter last year[18]. Cash Flow - The operating cash flow net amount for the year-to-date was ¥538,414.39, a significant decrease of 95.09% compared to the same period last year[5]. - The cash inflow from operating activities for the current period was ¥203,759,956.42, a decrease of 6.0% compared to ¥216,954,395.65 in the previous period[19]. - The net cash flow from operating activities was ¥538,414.39, significantly lower than ¥10,971,676.12 in the previous period, indicating a decline in operational efficiency[19]. - Cash outflow for purchasing goods and services increased to ¥34,645,255.46 from ¥24,617,513.56, representing a rise of 40.7%[19]. - The total cash outflow from financing activities was ¥22,277,458.00, up from ¥17,628,250.30, marking an increase of 26.8%[20]. - The net cash flow from financing activities was -¥6,277,458.00, compared to -¥1,628,250.30 in the previous period, indicating increased financial strain[20]. - The cash and cash equivalents at the end of the period decreased to ¥20,210,996.60 from ¥31,101,762.07, a decline of 35.2%[20]. - The cash received from tax refunds increased to ¥455,208.80 from ¥16,549.61, showing a significant improvement in cash flow from tax-related activities[19]. - The company did not report any cash inflow from investment activities, maintaining a consistent lack of investment returns[19]. Assets and Liabilities - The total assets at the end of the reporting period were ¥698,674,418.40, down 5.34% from the end of the previous year[5]. - Current assets totaled CNY 544,708,119.50, down from CNY 564,819,858.63, indicating a decrease of about 3.9%[14]. - Cash and cash equivalents decreased to CNY 20,710,678.29 from CNY 28,180,123.46, representing a decline of approximately 26.5%[14]. - Accounts receivable decreased to CNY 78,387,326.41 from CNY 100,116,017.59, a reduction of about 21.7%[14]. - Inventory increased to CNY 416,023,046.03 from CNY 408,764,642.59, showing a slight increase of approximately 1.5%[14]. - Non-current assets totaled CNY 153,966,298.90, down from CNY 173,258,603.92, reflecting a decrease of about 11.1%[14]. - The total liabilities increased to CNY 151,235,995.48, up from CNY 144,583,108.82, reflecting a growth of 4.5%[17]. - The total equity attributable to shareholders decreased to CNY 513,923,372.90 from CNY 557,240,851.04, a decline of 7.7%[17]. Research and Development - Research and development expenses for the reporting period were ¥21,816,849.53, a decrease of 52.67% year-on-year due to a reduction in R&D projects[10]. - The company's R&D expenses were CNY 21,816,849.53, significantly reduced by 52.7% from CNY 46,092,889.94 in the previous year[17]. - The company reported a significant reduction in development expenditures from CNY 15,580,000.00 to CNY 10,980,000.00, a decrease of approximately 29.8%[14]. Shareholder Information - The company reported a total of 100,517 ordinary shareholders at the end of the reporting period[10]. - The company has a total of 147,381,643 shares held by major shareholders, with the largest shareholder, Yu Qinfeng, holding 14.32%[11]. - The company has no outstanding preferred shareholders as per the report[12]. - The company is actively managing its shareholder structure, with significant pledges and freezes on shares held by major shareholders[11]. Future Outlook - Future outlook includes a commitment to enhance product development and market expansion strategies, although specific numerical targets were not provided[16]. - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[21].

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2023 - 4 1 号 江苏四环生物股份有限公司 在立案调查期间，陆克平先生将积极配合中国证券监督管理委员会的相关工 作。目前，公司各项生产经营活动正常有序开展。 关于实际控制人收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于今日接到实际控制人陆 克平先生通知，陆克平先生于 2023 年 10 月 9 日收到中国证券监督管理委员会下 发的《立案告知书》（编号：证监立案字 03720230095 号），因涉嫌证券市场操 纵违法违规，根据《中华人民共和国证券法》、《中华人民共和国行政处罚法》 等法律法规，中国证券监督管理委员会决定对其立案。 江苏四环生物股份有限公司 2023 年 10 月 9 日 1 公司将密切关注后续进展，并按照相关规定履行信息披露义务，敬请投资者 注意投资风险。 特此公告。 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥121,411,354.73, representing a 2.55% increase compared to ¥118,397,374.09 in the same period last year[19]. - The net loss attributable to shareholders was ¥37,775,397.48, which is a 14.72% increase in loss compared to ¥32,927,209.66 in the previous year[19]. - The net cash flow from operating activities decreased significantly by 88.63%, amounting to ¥808,121.15 compared to ¥7,105,657.94 in the same period last year[19]. - The total assets at the end of the reporting period were ¥712,555,161.73, down 3.46% from ¥738,078,462.55 at the end of the previous year[19]. - The company reported a basic earnings per share of -¥0.0367, a decrease of 14.69% from -¥0.0320 in the previous year[19]. - The weighted average return on net assets was -7.02%, compared to -5.58% in the previous year, indicating a decline in profitability[19]. - The company's revenue for the reporting period was CNY 121,411,354.73, representing a year-on-year increase of 2.55% compared to CNY 118,397,374.09[36]. - The company's R&D investment decreased by 51.85% to CNY 14,480,935.62 from CNY 30,076,280.23 in the previous year, indicating a reduction in ongoing projects[36]. - Sales expenses increased by 31.61% to CNY 65,807,996.66, attributed to increased market research and promotion efforts[36]. - The company reported a gross profit margin of approximately 28.5% for the first half of 2023, down from 30.0% in the previous year[126]. Assets and Liabilities - The total assets of the company as of the end of the first half of 2023 were CNY 715,471,458.50, slightly down from CNY 716,647,363.94 at the end of 2022[124]. - Total liabilities as of June 30, 2023, were CNY 159,179,908.88, up from CNY 144,583,108.82, representing an increase of about 10.1%[120]. - The company's total equity decreased to CNY 553,375,252.85 from CNY 593,495,353.73, a decline of approximately 6.8%[120]. - The company has no preferred shares or bonds outstanding as of the reporting date[111][120]. Cash Flow - The operating cash flow for the reporting period was CNY 808,121.15, a significant decrease of 88.63% compared to CNY 7,105,657.94 in the previous year[36]. - The company reported a cash outflow of ¥5,376,002.43 related to the repayment of lease liabilities during the reporting period[90]. - The total cash outflow from operating activities was 750,659.13 yuan in the first half of 2023, down from 1,682,891.36 yuan in the same period of 2022, indicating a reduction of approximately 55%[135]. - The total cash inflow from financing activities decreased to 27,560,000.00 yuan in the first half of 2023 from 41,302,000.70 yuan in the previous year, reflecting a decline of approximately 33.3%[136]. Research and Development - The company has five invention patents and three new drug certificates, highlighting its strong R&D capabilities[33]. - The company has invested 5.4 million yuan in research and development during the first half of 2023, reflecting a commitment to innovation[140]. - Research and development expenses decreased to CNY 14,480,935.62 in the first half of 2023 from CNY 30,076,280.23 in the same period of 2022, a reduction of about 52.1%[126]. Market and Sales - The company continues to focus on the production and sales of biopharmaceutical products, including recombinant human erythropoietin and granulocyte colony-stimulating factor injections[27]. - The company employs a sales model primarily through distributors, focusing on academic promotion and technical training to enhance product recognition[30]. - Domestic sales contributed ¥118,732,130.73, representing 97.79% of total revenue, while international sales increased to ¥2,679,224.00, accounting for 2.21%[37]. Environmental Compliance - The company is subject to strict environmental regulations and holds a valid Pollution Permit until July 14, 2027[61]. - The company has implemented measures to monitor and control emissions effectively[63]. - The company reported a stable operation of its wastewater treatment plant with a capacity of 120 tons per day, which was put into operation in December 2021 and has achieved standard discharge[65]. Corporate Governance - The company emphasizes the protection of minority shareholders' rights and has established a comprehensive corporate governance structure to ensure fair treatment[67]. - The company has set up various specialized committees within its board of directors to enhance governance and operational efficiency[67]. - The company adheres to timely and accurate information disclosure practices to protect the rights of all shareholders and stakeholders[67]. Legal Matters - The company has received a first-instance judgment dismissing all claims in a lawsuit related to securities false statements[51]. - The company reported no significant litigation or arbitration matters during the reporting period[79]. - There were no major related party transactions during the reporting period[81]. Future Outlook - Future outlook remains cautious due to ongoing market challenges and the need for strategic adjustments to improve profitability[127]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[142]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[146].

上市公司 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：江苏四环生物股份有限公司 金额单位：人民币元 | 非经营性资金 | | 占用方与上市公 | 上市公司核 | 2023 年期初占用 | 2023年1-6月占 | 2023年1-6月 | 2023 年 1-6 月偿 | 2023.6.30 占用 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | | 算的会计科 | | 用累计发生金 | 占用资金的 | | | | 占用性质 | | 占用 | | 司的关联关系 | 目 | 资金余额 | 额（不含利息） | 利息(如有) | 还累计发生金额 | 资金余额 | 原因 | | | 现 大 股 东 及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前 大 股 东 及 | | | | | | | | | | | | 其附 ...